CSPC PHARMA (01093.HK): Injectable Sirolimus (albumin-bound) received breakthrough therapy designation in China.

On February 28, Gelonghui reported that CSPC PHARMA (01093.HK) announced that its developed injectable sirolimus (albumin-bound) ("the product") has been granted breakthrough therapy designation by the National Medical Products Administration of the People's Republic of China, with the intended indication for monotherapy in malignant perivascular epithelioid cell tumors (PEComa) ("the indication").

Gelonghui FinanceFeb 28 05:00 ET

Express News | CSPC Pharmaceutical - Designation Granted by Nmpa China

ReutersFeb 28 04:56 ET

Express News | CSPC Pharmaceutical - Sirolimus for Injection (Albumin-Bound) Was Granted Breakthrough Therapy Designation in China

ReutersFeb 28 04:55 ET

Merrill Lynch: Maintains the 'Underperform' rating on CSPC PHARMA (01093) and lowers the Target Price to 4 HKD.

The company stated that the decline in revenue and Net income was mainly due to the drop in prices of JINYOLI and DOMISU in the JING-JIN-JI "3+N" alliance Pharmaceutical procurement, as well as XUANNING not being selected in the national eighth batch of procurement, leading to a year-on-year decline in income in the fields of cancer treatment and cardiology treatment of 28% and 15%, respectively.

Zhitong FinanceFeb 27 03:56 ET

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

The reevaluation of the Hong Kong stock Technology sector reveals that the Innovative Drugs sector is also expected to迎迎迎 DeepSeeK moment.

① Hong Kong stocks in the Biomedical sector are strengthening in the short term, which Bullish factors are worth paying attention to? ② The number of new drugs under research in our country has jumped to second in the Global ranking, what new support does the policy provide?

cls.cnFeb 26 04:01 ET